Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do companies typically provide 3rd party independent peer reviewed test results for a flagship over the counter dietary supplement that mostly hasn't even launched yet? :P It'd be nice if they did, but this isn't a FDA/EMA thing or clinical trials either.
Back to my point about people in a debate just shooting down the links and running with their premise anyway. :P If you want to consider this a red flag, be my guest, but I'd like to see a link showing what's scientifically inaccurate about those reports instead of rumors and hearsay trying to discredit the source.
The fact that we have reports at all (and a patent) is a green flag, unless they're all bogus. (prove it)
Agreed, and that's a bit of a yikes.
“In the five-day ECRM convention, we will educate buyers from retailers, such as Amazon, CVS Health, GNC, and Walgreens, about our 21st-century immune booster,” he added. “ECRM is the premiere program for buyers and manufacturers of new products. Meetings that used to take months to schedule now happen in a few days.”
Mr. Cotropia said health and wellness retailers should take notice of the Company’s new, effective immune booster. “We have a product that today’s consumers are looking for, especially because of the health crisis, and retailers understand what consumers want and need,” Mr. Cotropia said. “Enzolytics IPF Immune™ is the perfect product for 2022.” (source)
"We will be launching IPF Immune across multiple big and small retail chains, online platforms, in March 2022."
You're reaching a bit with this.
Snake oil? Or science? Show us the 3rd party independent, peer reviewed test results on the effectiveness! Post the link!
There's a lot of people on here saying all kinds of unsubstantiated stuff and sounding very confident. As the company gets closer to an important milestone month (March) it's very important to do your own DD!
(And no, this is not suspended!)
Afaik there's been no announce. There's a lot of FUD about it though.
I don't think ENZC would announce a R/S ahead of time, more likely just do it. They tend not to keep their shareholders in the loop about bookkeepy things until they make OTC filings. (We would know the day-of through our brokers.)
They also don't need a R/S if they can get a big enough catalyst to push share price up on its own. The current share structure isn't ideal for a company this size, but it's not terrible either if they delivered game-changing news.
With the market as bearish as it is right now, if ENZC or lenders have a lot of shares left to unload, they do probably need a R/S to avoid crushing PPS back to low pennies or trips - unless they can prop it up with news (like what's expected in March)
That ticker is drowning in toxic debt. Agreed a RS would be a risky move for ENZC unless they coupled it with game-changing news to drive a high demand for shares.
A reverse split is not always bad though, no value is inherently lost. Market cap stays the same. Share price goes up and liquidity goes down.
https://www.investopedia.com/ask/answers/what-stock-split-why-do-stocks-split/#toc-what-is-a-reverse-stock-split
It looks like they could use the "Market Value Standard" track in the Nasdaq Global Market to satisfy financial and liquidity requirements. (See page 8) I don't know if they're able to meet other requirements (audit trail, governance, etc).
Agreed that Nasdaq may not be realistic this year - but there are other tracks than revenue history and other tiers besides the premium Global Select Market.
https://listingcenter.nasdaq.com/assets/initialguide.pdf
https://www.otcmarkets.com/otcapi/company/financial-report/312797/content
Nasdaq would be nice because it'd open the doors to other investors and help shake off those MM's who just live in the OTC.
Has the company clarified what market it's planning to uplist to? I found this tweet from Godfather talking about the audit and uplisting to OTCQB (from Feb 2021, yep that's nearly a year ago) so maybe OTCQB is their target.
$ENZC - so why uplist to OTCQB ? Because, we will still be a publicly traded company and subsidiary to $GILD where common shares still exist and only ENZC controlling block (Preferred shares) are bought out. Don't know the full details of the agreement, but something like that.
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) February 24, 2021
They could do a reverse split, making shares scarce, then follow up with their first product to market and some huge announcement about ITV or mAbs. The former could bring their PPS above $4/share and the latter could hold it there for the 90 days needed to uplist straight to Nasdaq.
Pie in the sky, but afaik it's one way to fast track it.
https://listingcenter.nasdaq.com/assets/initialguide.pdf
That's been my experience as well!
Charts are just one tool of many. I encourage people to share their POV, because there's a great many ways to approach investing and we all have an opportunity to learn. (Tho, disrespectful communication is a distraction.)
If a chart's saying one thing, and people say it can't be so because they feel it shouldn't be so, that doesn't convince me to ditch the chart. I think there's a middle ground, at least to swing trading: some gut-feel, mixed with careful DD, TA, patience, risk management, and luck.
At any rate, the more perspectives the better!
Not necessarily! I showed the typical way to calculate the profit target (per investopedia) for this particular chart setup, but in my opinion there isn't enough time for sellers to drive the price as low as .02 before buying pressure increases in light of anticipated news. The lower the price goes, and the closer we get to news, the better the opportunity will seem for many investors who want shares before March.
A profit target of .02 means a short seller should plan to cover or take profits around that price. A reversal could happen or news could drop well before then, so there's no guarantee it'd get that low.
In a scenario where this keeps trending down, we should see the tug-of-war between buyers and sellers continue, and there'll be temporary reversals like we saw today.
Read it again, then - that number was addressed in the very next lines. :P
Chart says this has strong potential to keep trending down, it's less about price prediction and more about evaluating trend strengths and setups that might support runs or breakdowns. Profit targets are a part of it. Nothing is guaranteed but it's better than flying blind.
Agreed .0028 is way too low, when I redo the math on a logarithmic scale it's showing the short profit target at about .02, which also seems a bit low given there's only a few trading weeks before March. News trumps charts.
The downtrend makes sense given how red the market is and the fact the company keeps promising stuff and so far not delivering, give or take lenders unloading shares. That's a lot of sell pressure. Things may change for the better if ENZC can deliver in March, which is hopeful since they gave us a confident outlook and committed to an actual deliverable date (month). Nobody knows what the market will look like then, it could be a full on recession or an OTC renaissance or anything in between.
If you don't agree with the chart, (and don't shoot the messenger, lol) 1) what are you using that counters it, 2) what is your trend prediction, 3) how can you justify your prediction?
Thursday chart:
Trading slipped out of that triangle pattern and looks to be headed toward breakdown. It'd be awesome to see a rally Friday & Monday to form a double bottom at current levels, but I'm not holding my breath. (Plus the whole OTC is red.)
The price target for a breakout or breakdown from a symmetrical triangle is equal to the distance from the high and low of the earliest part of the pattern applied to the breakout price point.
https://www.investopedia.com/terms/s/symmetricaltriangle.asp
It's easier than that, just look for the garage full of shiny expensive cars! :)
It's currently trading in a triangle, and notice the lopsided head and shoulders materializing. This pattern has characterized much of the bear run since early last year.
So for this drop, support might happen around .07 (daily bollinger band low) or .056 (weekly bollinger / 200 week moving average) given the information available today. Something even lower is definitely possible, but March is coming fast with several expected catalysts.
Because it's still within the triangle, it has a chance to bounce higher from here if ENZC delivers a catalyst in the next few trading days or the market changes sentiment. (I'm not counting on either, but ynever know...) Remember this?
Installation of Equipment at VetProm Facility Enzolytics, Inc. purchased and installed equipment necessary for production of the ITV-1 immunotherapy for the clinical trials being design by Clinic Design. The original equipment had to be returned because of damage to the centrifuge which, along with other issues encountered by IMPL, delayed the scheduled production expected in October. The new expected production date has been rescheduled for January of 2022. (Page 22)
I wish I'd have found this in Sept 2020 :)
(.0005 a share)
They've come a long way.
A quick chart if you're swing trading:
There's a head and shoulders formation emerging here (bearish!) and I'm not seeing what would turn it around. The right shoulder itself is also a H&S which should help kick off additional downward price movement. Be aware of the short profit targets for a H&S pattern and how to calculate them: https://www.investopedia.com/terms/h/head-shoulders.asp
This kinda movement shouldn't matter as much to longs (unless they want a better price to add) and surprise news generally trumps charts.
4h chart (intraday captured 15 minutes to close):
Or the delay was so long that their contract expired with the first firm! The goalposts keep moving as we keep hearing variations of "soon". There was talk of the audit and uplist imminently happening at least ten months ago - we still haven't heard an official answer WHY it was delayed!
Not trying to be a downer, I'm hopeful we see delivery soonishly after Chandra's confident words today. :)
The only timeline I'm confident about from the interview is the one for IPF Immune, but that one's a doozy. :) Will be nice to see revenue through the rest of the year.
Just watched the interview! Some cliffnotes & DD:
Interview link:
1- IPF marketing campaign w/ TV Commercials. US Sales start in March 2022
2- ITV1 production and Africa Sales start in March/April, 2022
3- Diagnostics/Prognostics patent!
4- Tremendous Interest from #Gilead and #EliLilly on HIV mAbs Results
$ENZC 🎙INTERVIEW🎙
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) January 25, 2022
1️⃣ IPF marketing campaign w/ TV Commercials. US Sales start in March 2022 💥
2️⃣ ITV1 production and Africa Sales start in March/April, 2022
3️⃣ Diagnostics/Prognostics patent!
4️⃣ Tremendous Interest from #Gilead and #EliLilly on HIV mAbs Results 💥
Part 1. https://t.co/oSZrmV5FZT
A lot of price movement on relatively little volume. Hopefully bigger volume happens in this last hour.
No volume!
At the time of posting there's 10 minutes left in the market day and only about $41,500 worth of shares have changed hands in the last hour. (Which is where the green candle is coming from.) It'll fall right back down at close or open unless bigger volume comes in.
This is an interesting theory - that the lenders want their money and ENZC is required to facilitate conversions. ENZC probably couldn't tell us about it because other investors rushing to sell would pull the price down for lenders trying to dump shares, and they'd probably withhold news because the dumping would happen either way and crush momentum. This could be the NDA or "muzzle" some have wondered about. Am curious to see if there's anything about it on the next filing.
Also, I wonder if the odd Level 2 action we've been seeing is at least partially due to multiple MM's helping lenders unload shares. The coordination could be MMs having to account for each other's selling to dump as fast as possible without accidentally crashing the ticker.
It's been awhile since I checked many potential shares could be converted and dumped, maybe it's not as many as I'm thinking.
Thanks for your attention and analysis of Level 2 patterns, it's been very educational (and saved me and I'm sure many others a lot of money). Taking a break is healthy, I hope you can disconnect and enjoy it!
Oh I agree there's stuff that doesn't look organic at all, and stuff that looks to be blatant manipulation.
I could show charts for other tickers that follow the same general downward spiral as ENZC, but it'd be comparing apples to oranges since other tickers have different products, debt, are diluters, are in entirely different industries and so on. Or maybe that's the illustration, that stuff more or less trends the same regardless of market or milestone.
Point being that very few OTC's with accomplishments to their names have broken out of the usual pattern and achieved a more realistic valuation in spite of good news, partnerships, patents, products reaching market etc. By and large, the whole OTC pumped in early 2021 and has been declining since then across the board.
This ENZC volume breakdown from the last two weeks looks algorithmic. It's nearly a perfect curve. Doesn't pass the smell test.
The whole market is indeed being pulled down, and to me it doesn't look like organic trading. There's a lot of value in knowing how to read MMs' next play and I for one appreciate MP's Level 2 analysis. I don't think ENZC insiders have much to do with it.
I bet if the same scrutiny was applied to MM trading in other undervalued tickers we'd see similarities.
Yes, you're right. My mistake!
Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance , and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics.
It might be viewed as weak or delegitimizing for Chandra to blame market players for the trade patterns when the company hasn't delivered on some of its own key promises yet. MM's would know that and act accordingly. Doesn't necessarily imply an NDA, though that's also within the realm of possibility.
Contrary to another reply, ENZC did produce a whitepaper in collaboration with Intel, does have an agreement with Samsung to produce material for ITV-1 clinical trials, and was awarded those patents. All indications are they're bringing a product to North America. It doesn't appear to be a scam.
In 2021 ENZC also had a retracted PR with Lonza, at least one major lawsuit that the company didn't acknowledge until the last possible moment (filings), failure to deliver the audit, failure to deliver Montana results, late filings on occasion, etc. So it's not been pure accomplishment either.
But the tiny market cap vs the amount of IP, let alone this company's team and connections, doesn't make sense.
There's always the chance they'd drop another PR and use the talking points from that in the interview. That's not how it played out last time, but ynever know. They do already have a lot to talk about with Enzolytics IPF Immune coming to North America.
Mybad! You're right, I moved a decimal place!
A 3 billion market cap seems much more sustainable.
There are 2,797,935,953 outstanding shares, if they are even $1 apiece that would be a multi-trillion dollar market cap. (source) I could see it spiking that high briefly, but I don't see how it could sustain those prices without reverse split or a share reduction. Maybe that changes later when ITV-1 passes clinical trials or the mAbs tech reaches market. (Or maybe my expectations are too low.)
10000% gains from here would be a dream come true. I'd also be happy to see 100% gains that find support and stay there! GLTY
Here's hoping!
I'd like to see any one of my enormous list of watched tickers make a good hard run. :P Most of the green has been short teaser runs and dead cat bounces. A lot of favorable chart setups recently (probably crafted by MM algos) have totally fizzled.
ENZC has:
- Possible update on ITV-1 clinical trial materials manufacturing in January.
- Possible update on Enzolytics IPF Immune distribution deals.
- Ongoing legal affairs probably holding up other deliverables, with no timeline.
- Recent debt conversion (even into January?) with a lot of associated selling.
Parabolic might be possible if debt conversion is done, if Savov gets served (thanks Swamp Boy for the link) which per the article would leave him 20 days to cooperate or lose by default, and if we get one or both of the news catalysts. Would be cool if ENZC could be the stock that brings fresh life to the OTC.
It's saying that there are several resistance zones in play before this has room to really break out. The green dashed lines are price points where bulls and bears have historically fought to take control. (They align best as possible to the opens, closes and wicks of past chart candles.) Any such line above the current price acts as resistance, trying to stop the upward momentum.
Today EGYF closed at .128 which is testing the top boundary of Resistance Zone 1. If resistance breaks during the next trading day, the next place bears can try to rally would most likely be around .15 in Resistance Zone 2. Bears may sell hard at open Tuesday to keep the price inside Resistance Zone 1. (Markets are closed Monday for MLK day)
Rinse repeat up to the top of Resistance Zone 3 around .182. If bulls eventually break through that line, bulls take over the market for awhile. The "Blue Sky Breakout" is uncharted territory for this stock where the market hasn't determined any support or resistance lines yet.
My personal TA indicates the EGYF charts can support a run (Chartists: take a look at weekly Bollinger, RSI, MACD) but big volume needs to come in next week to confirm, and the company needs a catalyst (like known upcoming news) to sustain a bigger breakout. I'll be doing my DD over the weekend. I've been seeing lot of OTC tickers with favorable chart setups that appear to be carefully crafted by MM algorithms to sucker people into buying before the runs quickly fizzle. This is not investing advice.
Good choice imo.
.095ish is the next support which is at the daily Bollinger midline. Some indications it could bounce upward from there especially if we got an update on the materials production for ITV-1 trials. (Due in January per last update)
I do think the people dumping shares are just taking a break. If they dumped any faster this thing would crater. With this selling pressure I will be surprised if ENZC can hold its gains until more substantial news hits.
It's a Friday, and close to a short settlement date, watch for possible price action end of day.
(Chart is Intraday, today's candle hasn't closed yet)
(Bollinger bands are dashed pink lines and bold blue 20 day Moving Average)
(Dark to light blue are 200 MA, 50 MA, 20 MA, 9 MA)
Nice experiment & an interesting result.
It totally could. If they announce materials are ready for ITV-1 clinical trials and/or that's finally underway, it should get a nice pop!
Installation of Equipment at VetProm Facility Enzolytics, Inc. purchased and installed equipment necessary for production of the ITV-1 immunotherapy for the clinical trials being design by Clinic Design. The original equipment had to be returned because of damage to the centrifuge which, along with other issues encountered by IMPL, delayed the scheduled production expected in October. The new expected production date has been rescheduled for January of 2022. (Page 22)
End of week charts:
Super late with these and I'm exhausted so they're a bit messy. Added some observations and included blank charts so it's easy to save them out and flip between.
GLTA
Bull case:
This has momentum from recent and anticipated news.
Good chart setup on the daily and weekly. No daily breakout yet.
Some selling pressure but not like last month. Bears may be exhausted after their months-long selling season.
There appears to be lots of buying at Ask and no big selloff, likely there are fewer shares available in general.
Neutral case:
The surprise from recent news has worn off.
Big gap up on Friday, may need more filling.
Wedge shape on hourly shows this may need more consolidation.
Hourly AwesomeOscillator (bottom rightmost study) shows the bull trend cooling.
Falling back through the daily Bollinger band would likely kill the hype unless more news was forthcoming.
Likely support at 50 day MA around .105, which is also near the 9 week MA at .102, so it hopefully won't hard crash.
Bear case:
Two opportunities to run sputtered on Friday.
Investors may spook due to this stock's poor performance last year.
A sharp pullback on Monday could start a selling frenzy.
Friday's gap up, sustained high daily RSI, candles closing outside the daily Bollinger band, and having just crossed over the Bollinger midline on the weekly chart are all factors that could pull this down. (ie It might be time for bears to answer, especially if investors are still cautious after last year.)
Misc time periods w/ commentary
Weekly w/ commentary
Misc time periods, blank
Weekly, blank
Until it starts looking like a triangle, I can't chart a triangle. :P
It's less about prediction and more about evaluating trend strengths and setups that might support runs or breakdowns. Profit targets are a part of it. Nothing is guaranteed but it's better than flying blind.
It didn't break out of any chart ranges, and there wasn't high volume. Looks like MM's playing games to me.
I'll do end-of-week charts in a few hours. This is now trading in a symmetrical triangle (ie consolidating) and should resolve up or down sometime next week.
Was a big green week! Have a nice weekend! :)